Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $2.55 billion. The enterprise value is $5.07 billion.
Important Dates
The next estimated earnings date is Friday, August 8, 2025, before market open.
Earnings Date | Aug 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AMRX has 313.42 million shares outstanding. The number of shares has increased by 44.20% in one year.
Current Share Class | 313.42M |
Shares Outstanding | 313.42M |
Shares Change (YoY) | +44.20% |
Shares Change (QoQ) | +4.55% |
Owned by Insiders (%) | 46.71% |
Owned by Institutions (%) | 44.08% |
Float | 167.18M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 11.88 |
PS Ratio | 0.87 |
Forward PS | 0.81 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | 10.51 |
P/OCF Ratio | 8.30 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 8.37, with an EV/FCF ratio of 20.89.
EV / Earnings | n/a |
EV / Sales | 1.79 |
EV / EBITDA | 8.37 |
EV / EBIT | 13.91 |
EV / FCF | 20.89 |
Financial Position
The company has a current ratio of 1.40
Current Ratio | 1.40 |
Quick Ratio | 0.80 |
Debt / Equity | n/a |
Debt / EBITDA | 4.12 |
Debt / FCF | 10.64 |
Interest Coverage | 1.46 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | 6.67% |
Return on Invested Capital (ROIC) | 8.67% |
Return on Capital Employed (ROCE) | 15.91% |
Revenue Per Employee | $340,986 |
Profits Per Employee | -$1,572 |
Employee Count | 8,300 |
Asset Turnover | 0.83 |
Inventory Turnover | 3.07 |
Taxes
In the past 12 months, AMRX has paid $25.58 million in taxes.
Income Tax | 25.58M |
Effective Tax Rate | 44.10% |
Stock Price Statistics
The stock price has increased by +25.66% in the last 52 weeks. The beta is 1.05, so AMRX's price volatility has been similar to the market average.
Beta (5Y) | 1.05 |
52-Week Price Change | +25.66% |
50-Day Moving Average | 7.56 |
200-Day Moving Average | 8.12 |
Relative Strength Index (RSI) | 60.73 |
Average Volume (20 Days) | 1,837,583 |
Short Selling Information
The latest short interest is 5.35 million, so 1.71% of the outstanding shares have been sold short.
Short Interest | 5.35M |
Short Previous Month | 5.36M |
Short % of Shares Out | 1.71% |
Short % of Float | 3.20% |
Short Ratio (days to cover) | 3.37 |
Income Statement
In the last 12 months, AMRX had revenue of $2.83 billion and -$13.05 million in losses. Loss per share was -$0.04.
Revenue | 2.83B |
Gross Profit | 1.03B |
Operating Income | 364.20M |
Pretax Income | -55.01M |
Net Income | -13.05M |
EBITDA | 605.02M |
EBIT | 364.20M |
Loss Per Share | -$0.04 |
Full Income Statement Balance Sheet
The company has $61.63 million in cash and $2.58 billion in debt, giving a net cash position of -$2.52 billion or -$8.03 per share.
Cash & Cash Equivalents | 61.63M |
Total Debt | 2.58B |
Net Cash | -2.52B |
Net Cash Per Share | -$8.03 |
Equity (Book Value) | -59.39M |
Book Value Per Share | -0.42 |
Working Capital | 434.63M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $306.92 million and capital expenditures -$64.40 million, giving a free cash flow of $242.52 million.
Operating Cash Flow | 306.92M |
Capital Expenditures | -64.40M |
Free Cash Flow | 242.52M |
FCF Per Share | $0.77 |
Full Cash Flow Statement Margins
Gross margin is 36.48%, with operating and profit margins of 12.87% and -0.46%.
Gross Margin | 36.48% |
Operating Margin | 12.87% |
Pretax Margin | 2.05% |
Profit Margin | -0.46% |
EBITDA Margin | 21.38% |
EBIT Margin | 12.87% |
FCF Margin | 8.57% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -44.20% |
Shareholder Yield | -44.20% |
Earnings Yield | -0.51% |
FCF Yield | 9.52% |
Dividend Details Analyst Forecast
The average price target for AMRX is $11.50, which is 41.45% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.50 |
Price Target Difference | 41.45% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 1.52 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.52 |
Piotroski F-Score | 5 |